Mo-P4:237 Clinical course and prognosis of ischemic heart disease with stable angina pectoris (DATA of A5-year study)

2006 ◽  
Vol 7 (3) ◽  
pp. 98
Author(s):  
S. Evstifeeva ◽  
V. Lupanov ◽  
A. Samco ◽  
V. Naumov
Keyword(s):  
Heart Disease ◽  
Angina Pectoris ◽  
Ischemic Heart Disease ◽  
Stable Angina ◽  
Clinical Course ◽  
Ischemic Heart ◽  
Stable Angina Pectoris

scholarly journals Serum Fas/FasL levels in dependence on clinical presentations of coronary disease and their relationship with risk factors

2010 ◽  
Vol 67 (7) ◽  
pp. 537-542 ◽  
Author(s):  
Tatjana Ristic ◽  
Vidosava Djordjevic ◽  
Marina Deljanin-Ilic ◽  
Vladan Cosic ◽  
Slavica Kundalic
Keyword(s):  
Risk Factors ◽  
Heart Disease ◽  
Angina Pectoris ◽  
Ischemic Heart Disease ◽  
Stable Angina ◽  
Significant Positive Correlation ◽  
Density Lipoprotein ◽  
Stable Angina Pectoris ◽  
Normal Range ◽  
Significant Difference

Background/Aim. Ischemic heart disease is mostly a consequence of atherosclerosis. Besides the inflammation, the Fas/Fas ligand (FasL)/caspase death pathway is documented to be activated in atherosclerotic lesions. The aim of this study was to compare the values of soluble forms of Fas and FasL in patients with different presentations of coronary disease and to correlate Fas/FasL with risk factors. Methods. We studied 30 patients with chronic stable angina pectoris (SAP), 27 with non-stable angina pectoris (NSAP), and 39 with acute ST-elevation myocardial infarction (STEMI) and 27 age-matched healthy volunteers (the control group). Serum Fas/APO1 and FasL concentrations were determined using a commercially available enzymelinked immunoassays (ELISA). Results. Fas/APO-1 levels in the STEMI patients (6.981 ? 2.689 ng/mL) were significantly higher than Fas levels in the controls (5.092 ? 1.252 ng/mL, p < 0.01), but not significantly higher than Fas values in the SAP (5.952 ? 2.069 ng/mL) and the USAP patients (5.627?2.270 ng/ml). Levels of FasL did not show any significant difference among the studied groups. In the SAP patients Fas/APO1 showed a significant positive correlation with high sensitivity C-reactive protein (hsCRP) (p < 0.05) and a negative correlation with high-density lipoprotein cholesterol (HDL-C) (p < 0.05), while FasL showed a significant positive correlation with low-density lipoprotein cholesterol (LDL-C) (p < 0.05). Fas levels between the patients having cholesterol within normal range and those whose cholesterol was above the normal range showed a significant difference (p < 0.05) only in the NSAP patients. Fas and FasL levels between the patients with hsCRP lower than 3.0 mg/L and those with hsCRP higher than 3.0 mg/L of the SAP group showed a significant differences (p < 0.001, p < 0.05, respectively). Strong correlation between Fas concentration and diabetes mellitus (p < 0.05) and FasL concentrations and both cholesterol (p < 0.01) and triglycerides (p < 0.01) in the NSAP patients was observed. The patients in the SAP group showed no strong correlation between Fas and FasL concentration and risk factors. Conclusions. The obtained results showed that apoptotic process is dysregulated in the patients with ischemic heart disease. Interdependence between Fas and FasL and inflammatory and lipid markers as well as with cardiovascular risk factors was established.

scholarly journals Changes in the prevalence of metabolic syndrome and smoking habits during a 10-year period and relation between these risk factors and ischemic heart disease among men aged 45–64 years

Medicina ◽  
2008 ◽  
Vol 44 (5) ◽  
pp. 400 ◽  
Author(s):  
Dalia Lukšienė ◽  
Liucija Černiauskienė ◽  
Lilija Margevičienė ◽  
Abdonas Tamošiūnas
Keyword(s):  
Myocardial Infarction ◽  
Metabolic Syndrome ◽  
Heart Disease ◽  
Angina Pectoris ◽  
Ischemic Heart Disease ◽  
Density Lipoprotein ◽  
Epidemiological Studies ◽  
Ischemic Heart ◽  
Smoking Habits ◽  
Previous Myocardial Infarction

The aim of this work was to compare the prevalence of metabolic syndrome and smoking habits smokingduring a 10-year period and to evaluate the association between metabolic syndrome and smoking habits, and ischemic heart disease among Kaunas men aged 45–64 years. Material and methods. In this study, we have used data from two epidemiological studies, which had been carried out according to the MONICA study protocol (359 men aged 45–64 years were enrolled in 1992–1993 and 408 men aged 45–64 years – in 2001–2002). The association between metabolic syndrome and smoking habits, and ischemic heart disease was established according to the data of 2001–2002 years. Ischemic heart disease was diagnosed based on the following criteria: previous myocardial infarction, angina pectoris, or ischemic changes in electrocardiogram. Metabolic syndrome was defined by Adult Treatment Panel III (ATP III) criteria. Results. The prevalence of ischemic heart disease did not change among men aged 45–64 years during a 10-year period. During this period, the decreased prevalence of metabolic syndrome was observed; decreased rate of hyperglycemia, decreased high-density lipoprotein cholesterol level, increased rate of hypertriglyceridemia, and increased waist circumference were noted. During this period, the proportion of regular male smokers increased significantly. After the evaluation of association between and metabolic syndrome and smoking habits, and ischemic heart disease (according to the data of 2001–2002 years), it was determined that the highest rate of ischemic heart disease was among regular smokers with metabolic syndrome (32.3%), and the lowest rate of ischemic heart disease was noted among men who had never smoked and were without metabolic syndrome (11.6%) (OR=3.63; P=0.013). The highest rate of previous myocardial infarction and/or angina pectoris was determined among regular smokers with metabolic syndrome (19.4%), and the lowest rate of ischemic heart disease was determined among men who had never smoked and were without metabolic syndrome (3.6%) (OR=6.43; P=0.008). Conclusion. Combination of metabolic syndrome and smoking is significantly associated with ischemic heart disease among men aged 45–64 years.

A study on the clinical profile and risk factors of ischemic heart disease in women

2021 ◽  
Vol 19 (3) ◽  
pp. 130-132
Author(s):  
Sarath Kumar Reddy B ◽  
Keyword(s):  
Risk Factors ◽  
Heart Disease ◽  
Chest Pain ◽  
Ischemic Heart Disease ◽  
Stable Angina ◽  
Heart Diseases ◽  
Chronic Stable Angina ◽  
Clinical Profile ◽  
Ischemic Heart ◽  
Ischemic Heart Diseases

Background: Ischemic heart disease (IHD) is one of the principle causes of morbidity and of mortality in women1. Ischemic heart disease may manifest clinically as either chronic stable angina or acute coronary syndrome2 (ACS). Traditional risk factors (hypertension, diabetes, etc.) contribute to the development of IHD in both women and men. Some risk factors are unique to women (e.g., pregnancy-related complications, menopause), which cause increased mortality in women Aim: To study the risk factors and clinical profile of ischemic heart disease in women. Materials And Methods: Hospital-based prospective, cross-sectional study done in 50 patients with ischemic heart disease. Patients with a history of Chest pain suggestive of ischemic heart diseases and Electrocardiogram and cardiac biomarkers suggestive of ischemic heart disease were included in the study. Results: Maximum incidence of ischemic heart diseases is seen in the 6th decade. Mean age is 58.92 + 2.8years. 64%of the patients presented with chest pain, and 36% patients presented without any chest pain. After chest pain, the most common symptom was palpitations, seen in 56% patients, followed by sweating (44%). 30% presented to the medical facility within 3hours. 88% were diagnosed with acute coronary syndrome, and 12% were diagnosed with chronic stable angina. Women specific risk factors include the pregnancy-related complications seen in 10% patients, menopause attained in 86% patients, PCOS seen in 08% patients, use of oral contraceptive pills noticed in 08% patients, Other risk factors identified were hypothyroidism in 16% patients, connective tissue disorders like rheumatoid arthritis seen in 12% of the patients. Conclusion: Awareness regarding atypical symptoms as well as other symptoms of IHD should be created among women to avoid delayed complications. Simple lifestyle modifications like physical activity, diet modifications, etc., will reduce the number of women at risk for IHD.

scholarly journals Studies of the outcome of the treatment with beta-blockers in secondary prevention of the ischemic heart disease

2009 ◽  
Vol 62 (9-10) ◽  
pp. 450-455 ◽  
Author(s):  
Vesna Radovic
Keyword(s):  
Myocardial Infarction ◽  
Heart Disease ◽  
Angina Pectoris ◽  
Secondary Prevention ◽  
Ischemic Heart Disease ◽  
Beta Blockers ◽  
Convincing Evidence ◽  
Ischemic Heart ◽  
Necessary Condition ◽  
Professional Literature

Convincing evidence of the decline of mortality has been achieved with beta-blockers in patients with an acute myocardial infarction and in post-infarction follow-up. The beta-blockers are also the most efficient antianginal medications for the decrease of ischemia in outpatients. They are highly efficient as a monotherapy for angina and are also a medication of choice for angina after the coronary. The objective of this work was an estimate of the use of beta-blockers in secondary prevention of the ischemic heart disease and eliminating doubts concerning their prescription. The method of the analysis sums up the results of a twenty-five- year study on of the outcome of the treatment with beta-blockers in secondary prevention of the ischemic heart disease. The method of the work implies an examination of the professional literature and the data-bases, such as MEDLINE, PubMed and KOBSON. The first studies concerned non-selective beta-blockers, used orally. The following studies concerned cardioselective beta-blockers, metoprolol and atenolol. Several studies followed also the effect of beta-blockers and heparin, or beta-blockers and antagonists of calcium towards placebo, in patients with an unstable angina pectoris. Beta-blockers are an essential drug in secondary prevention of the myocardial infarction and in chronic heart failure. The necessary condition for the efficiency of beta-blockers is an early use. Beta-blockers should be given within 12 hours after the appearance of pain. The continuation of the therapy with beta-blockers after the acute phase is considered to be important in the decrease of the infarction zone expansion. Prophylactic use of beta-blockers after the coronary has an excellent effect, above all in patients with a minor, uncomplicated coronary. Though certain groups of beta-blockers have some special characteristics, when it comes to the treatment of angina pectoris, all beta-blockers are efficient. Generally, patients react well to them. Preference is given to cardioselective remedies, in patients with diabetes or lung disease. Exhaustive controlled clinical studies affirm beta-blockers as drugs that reduce mortality in secondary prevention of the ischemic heart disease.

scholarly journals Stable angina pectoris: choice of therapeutic tactics.

2018 ◽  
Vol 96 (1) ◽  
pp. 78-83
Author(s):  
Andrey A. Kirichenko
Keyword(s):  
Heart Disease ◽  
Angina Pectoris ◽  
Myocardial Ischemia ◽  
Stable Angina ◽  
Documentary Evidence ◽  
Stress Tests ◽  
Stable Angina Pectoris ◽  
Basic Principles ◽  
Transient Myocardial Ischemia ◽  
Positive Effect

In everyday practice, the basic principles of diagnosis and treatment of stable ischemic heart disease, set out in the clinical recommendations, are often not observed. For successful treatment of angina, first of all, it is necessary to verify the diagnosis. The diagnosis of stable angina pectoris can be considered sufficiently justified, provided the characteristic chest pain and documentary evidence of transient myocardial ischemia by stress tests. The patient should be evaluated as a whole, taking into account all existing diseases, since concomitant diseases can directly or indirectly exacerbate the course of coronary heart disease, and sometimes be the main cause of angina. In such cases, treatment of concomitant diseases has a pronounced positive effect on the course of angina pectoris. It is advisable to assess the magnitude of the coronary reserve, the severity and prevalence of transient myocardial ischemia, its impact on hemodynamics and, based on the analysis of these indicators, to identify patients with high or low risk of myocardial infarction. Revascularization brings a clear prognostic benefit only in subgroups at high risk.

Sign in / Sign up

Export Citation Format

Share Document